摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2-hydroxy-5-isopropyl-4-methoxyphenyl)-4-(1-methyl-1H-indol-5-yl)-1H-1,2,4-triazol-5(4H)-one | 1207598-30-8

中文名称
——
中文别名
——
英文名称
3-(2-hydroxy-5-isopropyl-4-methoxyphenyl)-4-(1-methyl-1H-indol-5-yl)-1H-1,2,4-triazol-5(4H)-one
英文别名
3-(2-hydroxy-4-methoxy-5-propan-2-ylphenyl)-4-(1-methylindol-5-yl)-1H-1,2,4-triazol-5-one
3-(2-hydroxy-5-isopropyl-4-methoxyphenyl)-4-(1-methyl-1H-indol-5-yl)-1H-1,2,4-triazol-5(4H)-one化学式
CAS
1207598-30-8
化学式
C21H22N4O3
mdl
——
分子量
378.431
InChiKey
PPQUPHAHCPVNAZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    28
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    79.1
  • 氢给体数:
    2
  • 氢受体数:
    4

文献信息

  • SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
    申请人:BlinkBio, Inc.
    公开号:US20170202970A1
    公开(公告)日:2017-07-20
    Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.
    本文描述了基于的共轭物,能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个-杂原子核心,一个或多个可选的催化基团,一个定位基团,允许共轭物在靶细胞或组织内积累,一个或多个有效载荷基团(例如,治疗剂或成像剂),以及与-杂原子核心共价结合的两个或更多个不干扰基团。
  • TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY
    申请人:Burlison Joseph A.
    公开号:US20100113447A1
    公开(公告)日:2010-05-06
    The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a pharmaceutical composition comprising such a compound.
    本发明涉及替代三唑化合物和包含替代三唑化合物的组合物。该发明进一步涉及在需要的主体中抑制Hsp90活性的方法,以及治疗过度增殖性疾病,如癌症,的方法,包括向该主体施用本发明的替代三唑化合物或包含这种化合物的药物组合物。
  • Triazole Compounds that Modulate HSP90 Activity
    申请人:Synta Pharmaceuticals Corp.
    公开号:US20150126499A1
    公开(公告)日:2015-05-07
    The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a pharmaceutical composition comprising such a compound.
    本发明涉及取代三唑化合物和包含取代三唑化合物的组合物。本发明进一步涉及抑制需要的Hsp90活性的方法以及治疗需要的高增殖性疾病,如癌症的方法,包括向受试者施用本发明的取代三唑化合物或含有这种化合物的药物组合物。
  • US8106083B2
    申请人:——
    公开号:US8106083B2
    公开(公告)日:2012-01-31
  • US8486932B2
    申请人:——
    公开号:US8486932B2
    公开(公告)日:2013-07-16
查看更多